Clinical Trial Update: Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial [Phase 3]

View source ↗

Summary

A Phase 3 trial (OPTIMUM) tested adding ixazomib or placebo to lenalidomide in patients with residual multiple myeloma. The study has completed and results have…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• NINLARO (ixazomib)
• Revlimid (lenalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2024-08-01